3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
14
Breast Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Urinary Bladder Neoplasms
4
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Lung Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Uterine Cervical Neoplasms
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms, Castration-Resistant
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Metastatic Solid Tumors
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
sacituzumab govitecan
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled